EGFR and esophageal squamous cell carcinoma: Furthermore, we showed in vitro that HER2- or EGFR-overexpressing ESCC was killed by Trastuzumab- or Cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC), respectively (Mimura et al, 2005b; Kawaguchi et al, 2007a, 2007b).